Zhongpei Huang
Key Laboratory Of Biological Targeted Therapy
Wuhan, China
Wuhan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Co-expression of IL-15 and CCL21 strengthens CAR-NK cells to eliminate tumors in concert with T cells and equips them with PI3K/AKT/mTOR signal signature.
Journal: Journal for immunotherapy of cancer
Published: May 28, 2025
Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies.
Journal: Cancer communications (London, England)
Published: June 07, 2023
circ_SPEF2 Regulates the Balance of Treg Cells by Regulating miR-16-5p/BACH2 in Lymphoma and Participates in the Immune Response.
Journal: Tissue engineering and regenerative medicine
Published: June 05, 2023
IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy.
Journal: Annals of hematology
Published: March 29, 2023
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects.
Journal: Signal transduction and targeted therapy
Published: December 29, 2022
Plasma proteomic and metabolomic signatures of B-ALL patients during CAR-T cell therapy.
Journal: Clinical and translational medicine
Published: December 01, 2022
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies.
Journal: Blood cancer journal
Published: November 23, 2022
Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphoma.
Journal: Cytotherapy
Published: November 12, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026